GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America.
'World Aids Day' Commemorated by GeoVax with Hope and Promise ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (BULLETIN BOARD: GOVX) , an Atlanta-based biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that the launch of...

Progress against HIV; Viral spread slows, but some groups at high risk.
Byline: Elizabeth Cooney More than two decades into the global HIV/AIDS epidemic, there are some encouraging signs of progress in preventing the spread of the virus, but certain groups still have stubbornly high burdens of disease. While 17,295 people are living with HIV/AIDS in Massachusetts,...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection.
SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is currently enrolling...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C.
Company reaffirms its innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to...

Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections.
--PS-Targeting Antibodies May Represent a Completely New Class of Drugs with Broad Potential to Treat Life-Threatening Viral Infections-- --Peregrine's Clinical-Stage Anti-PS Agent Bavituximab and Equivalent Antibodies Cured Lethal Viral Infections in Preclinical Models-- --Data Confirms PS is a 'Druggable' Target Common to a Number of...

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies.
- Patent for Antibodies that Directly Bind to Phospholipid Targets Covers All Viral Infections and All Combination Regimens - - Patent Issuance Follows Nature Medicine Publication Confirming the Broad Anti-Viral Potential of Anti-Phospholipid Approaches - TUSTIN, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. ,...

SIONIX Announces Positive Title-22 Drinking Water Analysis of Its Water Treatment System.
IRVINE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- James J. Houtz, president of SIONIX Corporation (BULLETIN BOARD: SINX) , today announced that SIONIX has completed a drinking water analysis in accordance with Title-22 of the California Code of Regulations of its containerized water treatment system at the Villa Park Dam in...

Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference.
CAMBRIDGE, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that Idenix management will participate in the PiperJaffray Annual Health Care Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at The New York Palace Hotel in New York, NY. The live and archived webcast of...